FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
LINCOLN, Neb., Nov. 09, 2016 -- National Research Corporation (NASDAQ:NRCIA) (NASDAQ:NRCIB) today announced that its Board of Directors has declared a quarterly cash dividend of $0.10 (ten cents) per Class A share and $.60 (sixty cents) per Class B share payable Friday, January 13, 2017, to shareholders of record as of the close of business on Friday, December 30, 2016.
For more than 35 years, National Research Corporation has been at the forefront of patient-centered care, helping healthcare providers measure and improve quality and services through analytics that offer a rich understanding of customers’ experiences, preferences, risks and behaviors across the healthcare continuum.
Kevin R. Karas Chief Financial Officer 402-475-2525
